As per Intent Market Research, the Point-Of-Care Infectious Disease Diagnostics Market was valued at USD 15.0 Billion in 2024-e and will surpass USD 24.8 Billion by 2030; growing at a CAGR of 8.8% during 2025-2030.
The Point-of-Care (POC) Infectious Disease Diagnostics Market is witnessing significant growth due to the increasing demand for rapid and accurate diagnostic solutions. The growing prevalence of infectious diseases, rising healthcare awareness, and advancements in diagnostic technologies have fueled market expansion. With the ongoing global emphasis on decentralized healthcare, POC diagnostic solutions are becoming more integral to early disease detection and timely intervention.
Lateral Flow Assays Segment is the Largest Owing to its Cost-Effectiveness and Rapid Results
Lateral flow assays (LFAs) dominate the POC infectious disease diagnostics market due to their affordability, ease of use, and rapid turnaround time. These assays are widely employed for diagnosing respiratory infections, sexually transmitted infections, and tropical diseases. Their portability and minimal infrastructure requirements make them particularly useful in resource-limited settings.
The widespread adoption of LFAs in detecting infectious diseases like COVID-19 and influenza has further propelled their growth. With continuous improvements in assay sensitivity and specificity, their applications are expanding beyond traditional infectious disease detection to include broader public health screening initiatives.
.JPG)
Respiratory Infections Segment Leads Due to High Disease Burden and Testing Demand
Respiratory infections, including COVID-19, influenza, and tuberculosis (TB), represent the largest disease segment due to their high incidence rates and impact on public health. The COVID-19 pandemic significantly accelerated the adoption of rapid diagnostic tests, with a notable increase in antigen and molecular-based testing for quick identification of respiratory pathogens.
As emerging viral strains continue to pose threats, rapid diagnostic tests remain crucial in containing outbreaks and preventing transmission. Increased government investments and healthcare policies supporting point-of-care testing further strengthen this segment’s growth trajectory.
Blood Sample Segment is the Largest Due to Broad Disease Coverage
The blood sample segment dominates the market as it is widely used for diagnosing bloodborne infections like HIV, Hepatitis B & C, as well as bacterial and viral infections. Blood-based diagnostics offer high sensitivity and accuracy, making them essential for critical infectious disease detection.
Advancements in microfluidic and biosensor technologies have enhanced the efficiency of blood-based POC tests, reducing turnaround time while maintaining diagnostic accuracy. These tests are extensively used in hospitals, laboratories, and field-based screening programs worldwide.
Home Care Settings are the Fastest-Growing End-User Segment Due to Self-Testing Trends
The home care settings segment is expanding rapidly due to increased consumer preference for self-testing kits. The rise of at-home diagnostic solutions, particularly for diseases like COVID-19, HIV, and influenza, has significantly contributed to this trend. Convenience, affordability, and growing awareness about self-health monitoring are key drivers.
Companies are launching advanced home-based diagnostic kits equipped with digital connectivity features, allowing users to share test results with healthcare professionals in real time. This shift towards decentralized testing is expected to continue, driving further growth in the segment.
PCR-Based Testing Dominates Due to High Sensitivity and Accuracy
PCR-based testing holds the largest share in the technology segment due to its high accuracy, sensitivity, and ability to detect low viral loads. Polymerase Chain Reaction (PCR) tests are widely used for diagnosing respiratory infections, bloodborne diseases, and sexually transmitted infections.
Despite being costlier and requiring specialized equipment, PCR remains the gold standard for many infectious disease diagnostics. Technological advancements, such as the development of portable PCR devices, are making this method more accessible at the point of care, sustaining its dominance in the market.
North America is the Largest Market Due to Advanced Healthcare Infrastructure
North America leads the regional segment due to its well-established healthcare system, high adoption of advanced diagnostic technologies, and strong regulatory support. The presence of major industry players and continuous investments in research and development further bolster market growth.
Additionally, government initiatives promoting early disease detection and the rising incidence of infectious diseases drive demand for point-of-care diagnostic solutions. The U.S. remains a key contributor, with an increasing focus on rapid testing and disease surveillance programs.
.JPG)
Competitive Landscape
The POC infectious disease diagnostics market is highly competitive, with major players such as Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific, BD (Becton, Dickinson and Company), and BioMérieux leading the industry. Companies are actively investing in product innovation, strategic collaborations, and regulatory approvals to strengthen their market position.
The competitive landscape is characterized by frequent product launches, mergers & acquisitions, and advancements in diagnostic technologies. The emphasis on developing portable, high-sensitivity, and cost-effective diagnostic solutions is expected to shape the future of the market, ensuring continued growth and technological evolution.
List of Leading Companies:
- Abbott Laboratories
- Roche Diagnostics
- Siemens Healthineers
- Thermo Fisher Scientific
- Becton, Dickinson and Company (BD)
- BioMérieux
- Danaher Corporation
- Qiagen
- Hologic, Inc.
- Cepheid
- PerkinElmer, Inc.
- QuidelOrtho Corporation
- Luminex Corporation
- Meridian Bioscience
- GenMark Diagnostics
Recent Developments:
- Abbott introduced a new combined COVID-19 and influenza rapid test to enhance early detection in healthcare settings.
- Roche acquired a molecular diagnostics company to strengthen its infectious disease diagnostics capabilities.
- Siemens gained regulatory approval for a novel rapid HIV detection kit designed for decentralized healthcare facilities.
- Becton, Dickinson and Company announced a collaboration with public health organizations to improve access to rapid tuberculosis diagnostics.
- Qiagen launched a portable, highly sensitive malaria detection kit to enhance disease control efforts in endemic regions.
Report Scope:
|
Report Features |
Description |
|
Market Size (2024-e) |
USD 15.0 Billion |
|
Forecasted Value (2030) |
USD 24.8 Billion |
|
CAGR (2025 – 2030) |
8.8% |
|
Base Year for Estimation |
2024-e |
|
Historic Year |
2023 |
|
Forecast Period |
2025 – 2030 |
|
Report Coverage |
Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments |
|
Segments Covered |
Point-Of-Care Infectious Disease Diagnostics Market By Product Type (Lateral Flow Assays, Molecular Diagnostics, Immunoassays, Biosensors), By Disease Type (Respiratory Infections, Sexually Transmitted Infections, Gastrointestinal Infections, Bloodborne Infections, Tropical & Vector-Borne Diseases, Urinary Tract Infections), By Sample Type (Blood, Urine, Saliva, Nasal & Throat Swabs, Stool), By End-User (Hospitals & Clinics, Diagnostic Laboratories, Home Care Settings, Research Institutes, Pharmacies), By Technology (PCR-Based Testing, Isothermal Nucleic Acid Amplification, Loop-Mediated Isothermal Amplification (LAMP), Microfluidics, Lateral Flow Technology) |
|
Regional Analysis |
North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa) |
|
Major Companies |
Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific, Becton, Dickinson and Company (BD), BioMérieux, Danaher Corporation, Qiagen, Hologic, Inc., Cepheid, PerkinElmer, Inc., QuidelOrtho Corporation, Luminex Corporation, Meridian Bioscience, GenMark Diagnostics |
|
Customization Scope |
Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements |
Frequently Asked Questions
The Point-Of-Care Infectious Disease Diagnostics Market was valued at USD 15.0 Billion in 2024-e and is expected to grow at a CAGR of over 8.8% from 2025 to 2030
Isothermal nucleic acid amplification is witnessing rapid adoption due to its high accuracy and speed in detecting infectious diseases.
North America dominates the market due to advanced healthcare infrastructure, high adoption rates, and significant R&D investments.
Challenges include regulatory hurdles, accuracy concerns in low-resource settings, and high costs of advanced diagnostic technologies.
|
1. Introduction |
|
1.1. Market Definition |
|
1.2. Scope of the Study |
|
1.3. Research Assumptions |
|
1.4. Study Limitations |
|
2. Research Methodology |
|
2.1. Research Approach |
|
2.1.1. Top-Down Method |
|
2.1.2. Bottom-Up Method |
|
2.1.3. Factor Impact Analysis |
|
2.2. Insights & Data Collection Process |
|
2.2.1. Secondary Research |
|
2.2.2. Primary Research |
|
2.3. Data Mining Process |
|
2.3.1. Data Analysis |
|
2.3.2. Data Validation and Revalidation |
|
2.3.3. Data Triangulation |
|
3. Executive Summary |
|
3.1. Major Markets & Segments |
|
3.2. Highest Growing Regions and Respective Countries |
|
3.3. Impact of Growth Drivers & Inhibitors |
|
3.4. Regulatory Overview by Country |
|
4. Point-Of-Care Infectious Disease Diagnostics Market, by Product Type (Market Size & Forecast: USD Million, 2023 – 2030) |
|
4.1. Lateral Flow Assays |
|
4.2. Molecular Diagnostics |
|
4.3. Immunoassays |
|
4.4. Biosensors |
|
5. Point-Of-Care Infectious Disease Diagnostics Market, by Disease Type (Market Size & Forecast: USD Million, 2023 – 2030) |
|
5.1. Respiratory Infections (Influenza, COVID-19, Tuberculosis) |
|
5.2. Sexually Transmitted Infections (HIV, HPV, Syphilis, Chlamydia, Gonorrhea) |
|
5.3. Gastrointestinal Infections (Hepatitis, Norovirus, Rotavirus) |
|
5.4. Bloodborne Infections (HIV, Hepatitis B & C) |
|
5.5. Tropical & Vector-Borne Diseases (Malaria, Dengue, Zika) |
|
5.6. Urinary Tract Infections |
|
6. Point-Of-Care Infectious Disease Diagnostics Market, by Sample Type (Market Size & Forecast: USD Million, 2023 – 2030) |
|
6.1. Blood |
|
6.2. Urine |
|
6.3. Saliva |
|
6.4. Nasal & Throat Swabs |
|
6.5. Stool |
|
7. Point-Of-Care Infectious Disease Diagnostics Market, by End-User (Market Size & Forecast: USD Million, 2023 – 2030) |
|
7.1. Hospitals & Clinics |
|
7.2. Diagnostic Laboratories |
|
7.3. Home Care Settings |
|
7.4. Research Institutes |
|
7.5. Pharmacies |
|
8. Regional Analysis (Market Size & Forecast: USD Million, 2023 – 2030) |
|
8.1. Regional Overview |
|
8.2. North America |
|
8.2.1. Regional Trends & Growth Drivers |
|
8.2.2. Barriers & Challenges |
|
8.2.3. Opportunities |
|
8.2.4. Factor Impact Analysis |
|
8.2.5. Technology Trends |
|
8.2.6. North America Point-Of-Care Infectious Disease Diagnostics Market, by Product Type |
|
8.2.7. North America Point-Of-Care Infectious Disease Diagnostics Market, by Disease Type |
|
8.2.8. North America Point-Of-Care Infectious Disease Diagnostics Market, by Sample Type |
|
8.2.9. North America Point-Of-Care Infectious Disease Diagnostics Market, by End-User |
|
8.2.10. By Country |
|
8.2.10.1. US |
|
8.2.10.1.1. US Point-Of-Care Infectious Disease Diagnostics Market, by Product Type |
|
8.2.10.1.2. US Point-Of-Care Infectious Disease Diagnostics Market, by Disease Type |
|
8.2.10.1.3. US Point-Of-Care Infectious Disease Diagnostics Market, by Sample Type |
|
8.2.10.1.4. US Point-Of-Care Infectious Disease Diagnostics Market, by End-User |
|
8.2.10.2. Canada |
|
8.2.10.3. Mexico |
|
*Similar segmentation will be provided for each region and country |
|
8.3. Europe |
|
8.4. Asia-Pacific |
|
8.5. Latin America |
|
8.6. Middle East & Africa |
|
9. Competitive Landscape |
|
9.1. Overview of the Key Players |
|
9.2. Competitive Ecosystem |
|
9.2.1. Level of Fragmentation |
|
9.2.2. Market Consolidation |
|
9.2.3. Product Innovation |
|
9.3. Company Share Analysis |
|
9.4. Company Benchmarking Matrix |
|
9.4.1. Strategic Overview |
|
9.4.2. Product Innovations |
|
9.5. Start-up Ecosystem |
|
9.6. Strategic Competitive Insights/ Customer Imperatives |
|
9.7. ESG Matrix/ Sustainability Matrix |
|
9.8. Manufacturing Network |
|
9.8.1. Locations |
|
9.8.2. Supply Chain and Logistics |
|
9.8.3. Product Flexibility/Customization |
|
9.8.4. Digital Transformation and Connectivity |
|
9.8.5. Environmental and Regulatory Compliance |
|
9.9. Technology Readiness Level Matrix |
|
9.10. Technology Maturity Curve |
|
9.11. Buying Criteria |
|
10. Company Profiles |
|
10.1. Abbott Laboratories |
|
10.1.1. Company Overview |
|
10.1.2. Company Financials |
|
10.1.3. Product/Service Portfolio |
|
10.1.4. Recent Developments |
|
10.1.5. IMR Analysis |
|
*Similar information will be provided for other companies |
|
10.2. Roche Diagnostics |
|
10.3. Siemens Healthineers |
|
10.4. Thermo Fisher Scientific |
|
10.5. Becton, Dickinson and Company (BD) |
|
10.6. BioMérieux |
|
10.7. Danaher Corporation |
|
10.8. Qiagen |
|
10.9. Hologic, Inc. |
|
10.10. Cepheid |
|
10.11. PerkinElmer, Inc. |
|
10.12. QuidelOrtho Corporation |
|
10.13. Luminex Corporation |
|
10.14. Meridian Bioscience |
|
10.15. GenMark Diagnostics |
|
11. Appendix |
A comprehensive market research approach was employed to gather and analyze data on the Point-Of-Care Infectious Disease Diagnostics Market . In the process, the analysis was also done to analyze the parent market and relevant adjacencies to measure the impact of them on the Point-Of-Care Infectious Disease Diagnostics Market . The research methodology encompassed both secondary and primary research techniques, ensuring the accuracy and credibility of the findings.
.jpg)
Secondary Research
Secondary research involved a thorough review of pertinent industry reports, journals, articles, and publications. Additionally, annual reports, press releases, and investor presentations of industry players were scrutinized to gain insights into their market positioning and strategies.
Primary Research
Primary research involved conducting in-depth interviews with industry experts, stakeholders, and market participants across the E-Waste Management ecosystem. The primary research objectives included:
- Validating findings and assumptions derived from secondary research
- Gathering qualitative and quantitative data on market trends, drivers, and challenges
- Understanding the demand-side dynamics, encompassing end-users, component manufacturers, facility providers, and service providers
- Assessing the supply-side landscape, including technological advancements and recent developments
Market Size Assessment
A combination of top-down and bottom-up approaches was utilized to analyze the overall size of the Point-Of-Care Infectious Disease Diagnostics Market . These methods were also employed to assess the size of various subsegments within the market. The market size assessment methodology encompassed the following steps:
- Identification of key industry players and relevant revenues through extensive secondary research
- Determination of the industry's supply chain and market size, in terms of value, through primary and secondary research processes
- Calculation of percentage shares, splits, and breakdowns using secondary sources and verification through primary sources
.jpg)
Data Triangulation
To ensure the accuracy and reliability of the market size, data triangulation was implemented. This involved cross-referencing data from various sources, including demand and supply side factors, market trends, and expert opinions. Additionally, top-down and bottom-up approaches were employed to validate the market size assessment.